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Summary
AIM: Mortality rates of COVID-19 patients hospitalised in
intensive care units (ICUs) are generally high. Availabili-
ty of ICU resources might influence clinical outcomes. The
aim of this study was to examine the clinical course of the
42 patients treated during the first epidemic wave between
2 March and 20 May 2020 at the tertiary ICU of the Bern
University Hospital, where staffing, equipment and drugs
were not limited.
METHODS: For this descriptive study, retrospective data
of the first COVID-19 wave in an interdisciplinary adult ICU
of a Swiss University hospital was used. The study in-
cluded data regarding healthcare staffing and COVID-19
patients. The primary outcome was the ICU mortality in
COVID-19 patients.
RESULTS: Patients’ median age was 61 years (range
32–86), simplified acute physiology score (SAPS-II) was
46 (13–90), 81% of the patients were males, 79% were
mechanically ventilated (3 of them on extracorporeal
membrane oxygenation), 31% were under renal replace-
ment therapy and 21% received steroids. All patients were
fully anticoagulated from the time of admission. No off-la-
bel experimental antiviral or anti-inflammatory drugs were
used with the exception of one patient, and antibiotic pre-
scription was restrictive. Nurse-to-patient ratio was 1:1
during all shifts, and the physician-to-patient ratio was 1:4
(day shift) and 1:10 (night shift). Infectious disease spe-
cialists and physiotherapists were present every day. The
median ICU length of stay was 10 days (1–38) days, and
ICU and hospital mortality rates were 7% and 12%, re-
spectively.
CONCLUSION: Careful intensive care treatment, without
off-label drug use but including steroids in selected cases,
combined with an interdisciplinary approach and provision
of sufficient human resources, were associated with low
ICU and hospital mortality rates despite high disease
severity. Availability of qualified human resources may
have an important impact on the outcome of COVID-19.
Introduction
As of August 2020, more than 25 million individuals had
been infected worldwide with SARS-CoV-2, and more
than 800,000 patients had died from this infection. Risk
factors for the development of severe disease (COVID-19)
and death include on the one hand older age and comor-
bidities such as diabetes mellitus or coronary heart dis-
eases, and on the other hand severe inflammation and co-
agulation abnormalities [1–3]. Reported hospital mortality
rates due to COVID-19 range between 30% and 80% in
critically ill patients [4–8]. Lausanne University Hospital
Intensive Care Unit (ICU), much harder hit than our ICU,
reported a 29% mortality rate in mechanically ventilated
COVID-19 patients [9]. A number of experimental thera-
pies have been proposed, but only a few have demonstrat-
ed positive results [10, 11]. Staffing, availability of drugs
and equipment, and the rate of admission are likely to in-
fluence course and outcome of the disease [12–14]. Here
we report a very low mortality rate of patients treated in a
tertiary university ICU in Switzerland. We hypothesise that
the sufficient availability of well-trained ICU staff, drugs
and special equipment, together with the best standard of
ICU supportive care, has been one of the main reasons for
the high survival rate observed.
Methods
All patients with COVID-19 admitted to the Bern Uni-
versity Hospital ICU between 2 March and 20 May, the
first wave of COVID-19 in Switzerland, were included in
the study. This descriptive study was approved by the lo-
cal Ethics Committee (# 2020-00638), and informed con-
sent was waved owing to its descriptive nature. Some pa-
tients were also included in other COVID-projects
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The ICU at the Bern University Hospital treats adult pa-
tients and serves as primary, secondary and tertiary ICU
for a recruiting region of around 1 million inhabitants. The
hospital has approximately 900 beds, and the ICU has 39
beds to which are affiliated additional 16 intermediate care
beds. On average, the personnel coverage per bed is 5.4
nurses (physicians: 1.0), which allows for a 1:1 nurse/pa-
tient ratio. The percentage of certified critical care nurs-
es is 60% and the percentage of physicians with an FMH
designation of intensive care specialist is 50%. The man-
agement strategies for COVID-19 patients in the hospital
were defined and updated during weekly face-to-face in-
terprofessional meetings with specialists in intensive care
(physicians, critical care nurses), infectious diseases, pneu-
mology, internal medicine, rheumatology and emergency
medicine. This hospital expert group decided at the begin-
ning of the first wave against off-label experimental an-
tiviral or anti-inflammatory treatment outside randomised
clinical trials (e.g., World Health Organization Solidar-
ity Trial). Treatments including hydroxychloroquine, ri-
tonavir-boosted lopinavir, remdesivir, or tocilizumab were
thus not prescribed and even stopped at ICU admission
when patients were referred from other hospital with such
treatments, with the exception of one first patient who re-
ceived remdesivir for 4 days at the beginning of the first
epidemic wave.
The main reasons for ICU admission were respiratory fail-
ure, defined as the presence of one of the following cri-
teria: respiratory rate >30/min and clinical signs of respi-
ratory distress, hypoxaemia defined as oxygen saturation
(SpO2) <90% despite O2 supply >6 l/min, lactic acidosis
or shock. All SARS-CoV-2-infected patients who qualified
for ICU care using the standard admission criteria at our
institution were treated in the ICU. Triage was performed
round the clock by a certified ICU physician in agreement
with the physician in charge in the emergency room (ER)
or on the ward. Patients with respiratory failure were im-
mediately intubated without any noninvasive ventilation or
high-flow oxygen attempt. We used the oesophageal pres-
sure to calculate transpulmonary pressure (Ptp). The goal
was to achieve end-expiratory values slightly above 0 mm
Hg, and driving pressures ≤15 mm Hg with tidal values ≤6
ml/kg bodyweight, in order to keep plateau airway pres-
sure <30 mm Hg. Moreover, patients with acute respira-
tory distress syndrome (ARDS) were turned to prone po-
sitions for 16 hours/day as long as paO2/FiO2 (ratio of
arterial oxygen partial pressure to fractional inspired oxy-
gen) increased with protective ventilator settings using oe-
sophageal catheters for transpulmonary pressure monitor-
ing. Sedation was initially performed with propofol (or
midalzolam for haemodynamically unstable patients) and
fentanyl continuous infusions. Later, dexmedetomidine or
intermittent sedation with benzodiazepine or neuroleptic
drugs were used. Muscle relaxation was applied during the
first 48 hours, longer if needed to ensure protective lung
ventilation, and always during the prone position.
During the study period corresponding to the first epidemic
wave in Switzerland, i.e., before the publication of the Re-
covery trial [10], steroids were not administered routinely,
but only in the absence of bacterial superinfection to pa-
tients with late unresolving ARDS according to the proto-
col recently published [15]. Antibiotics or antifungals were
prescribed only if strong evidence of superinfection was
present. Required criteria were fever, new or increasingly
dense lung infiltrates in chest X-ray or computed tomog-
raphy (CT)-scan, increasing C-reactive protein (CRP), and
procalcitonin. In primarily immunocompromised patients,
antibiotic administration was preceded by a broncho-alve-
olar lavage performed by a pneumologist, or at least by a
blind tracheal aspiration, for microbiology diagnostic pur-
poses. Fungal superinfection was also screened for by cul-
ture and serology. Extracorporeal membrane oxygenation
(ECMO) was used during the early stay in the ICU if
paO2/FiO2 was <50 mm Hg in patients not responding
to optimised ventilator settings, recruitment and negative
fluid balance. Negative fluid balance was attempted by
furosemide infusion, intermittent dialysis or continuous
veno-venous haemodiafiltration (CVVHDF). Heart func-
tion was monitored by frequent echocardiography. Imme-
diately after ICU admission and during the first phase
of the therapy, all patients received a pulmonary artery
catheter to monitor the effects of ventilator settings, prone
positioning and haemodynamic management, especially
aggressive negative fluid balance, on oxygen delivery.
High-dose prophylactic anticoagulation using unfraction-
ated heparin was prescribed in all patients to reach an anti-
factor Xa activity between 0.25 and 0.35 IU/l. Enteral nu-
trition was administered according to a local protocol, with
the aim of delivering 75% of required calories within the
first 72 h after ICU admission. The course of each patient
was analysed and discussed with infectious disease spe-
cialists daily; physiotherapists were available during the
daytime, 7 days a week. We employed an early mobilisa-
tion regimen; physiotherapists and advanced practice nurs-
es assisted in turning the patients. Patient data were col-
lected, recorded and stored in a clinical information system
(Centricity® Critical Care 8.1 SP10, GE Health Care, Bar-
rington, IL, USA). The system stores 2-minute medians for
artefact removal. All descriptive analyses of the described
variables were performed using SPSS Statistics 26. Fre-
quencies were indicated as numbers and %, and continuous
variables as median and range.
Results
Between 2 March and 20 May, 42 patients with COVID-19
were treated in the Bern University Hospital Intensive Care
Unit. Median age was 61 years (range 32–86), most of
them were males (81%). The most frequent risk factors for
severe SARS-CoV-2 infection reported were arterial hy-
pertension (n = 12, 29%) and diabetes (n = 12, 29%). Sim-
plified acute physiology score (SAPS-II) during the first
24 h of ICU stay was 46 (13–90). Overall, 79% of the pa-
tients were mechanically ventilated (3 of them on ECMO)
(fig. 1), 31% were under renal replacement therapy, and
21% received steroids. All patients were fully anticoagu-
lated from time of admission. No off-label experimental
antiviral or anti-inflammatory drugs were used with the ex-
ception of one patient, and antibiotic prescription was re-
strictive.
The time course of disease severity and interventions are
displayed in the table 1.
Maximum neutrophil/lymphocyte ratio was 7.1 (0.9–35.0),
maximum D-dimers were 2475 µg/l (559–79,632).
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The nurse-to-patient ratio was 1:1 during all shifts, and
the physician-to-patient ratio was 1:4 (day shift) and 1:10
(night shift). Infectious disease specialists and physiother-
apists were present every day. Therapeutic Intervention
Scoring System (TISS) 28 points per admission increased
compared with March-May 2019 (248 vs 202 points),
whereas TISS 28 points per full time equivalent (FTE) did
not, since the total number of admissions decreased com-
pared with March-May 2019, and the FTE/bed could be
maintained.
Median length of ICU stay was 10 days (1–38) (fig. 2). We
transferred 22 patients to internal medicine and pneumol-
Figure 1: Length of mechanical ventilation. ICU = Intensive Care
Unit.
ogy, 11 patients to the ICU of their respective hospital re-
gion after clinical improvement, 4 patients to an external
ward, and 2 patients to neighbouring countries. ICU and
hospital mortality were 7% and 12%, respectively (fig. 3).
Discussion
During the first epidemic SARS-CoV-2 wave, we observed
a relatively low mortality among the 42 patients with
COVID-19 admitted to the Bern University Hospital ICU.
A low mortality was seen despite patients being severely
affected with high neutrophil/lymphocyte ratios and D-
dimers. The average SAPS-II scores, and signs of inflam-
mation and coagulation disturbances were comparable to
Figure 2: Length of intensive care unit (ICU) stay.
Table 1: Time course of disease severity and therapeutic interventions in the ICU.
ICU Day 1
n in ICU (d1) = 42
Day 2-3
n in ICU (d2) = 35
Day 4-7
n in ICU (d4) = 30
Day 8-14
n in ICU (d8) = 25
Day 15-21
n in ICU (d15) = 16
Day 21-28
n in ICU (d21) = 7
Continuous sedation / analgesia / muscle re-
laxation
– Analgesia (n) 30 29 26 24 10 6
– Sedation (n) 27 28 24 17 4 5
– Relaxation (n) 22 22 16 11 1 1
Max / min RASS (median) 0 / –4.5 0 / –5 1 / –5 1 / –4 1 / –2 1 / –2
Mechanical ventilation
– Mechanical ventilation (n) 34 30 28 23 13 6
– Highest PEEP (cm H2O) 14 (6–20) 14 (5–28) 14 (5–28) 11 (5–30) 8 (5–30) 5 (4–27)
– Min compliance (ml / cm H2O) 38 (15–71) 38 (15–68) 37 (4–75) 36 (4–64) 23 (10–55) 34 (34–34)
Prone position (n) 9 12 10 7 1 0
Dialysis
– Continuous (n) 2 5 6 8 3 1
– Intermittent (n) 0 0 3 7 3 2
Catecholamines
– Noradrenaline (n) 19 23 17 11 6 2
– Dobutamine (n) 2 5 2 3 1 0
Lowest CO (l/min) 5.8 (3.3–8.8) 5.7 (3.4–8.8) 5 (3.9–8.7) 5.6 (3.2–9.3) NA NA
Lowest SvO2 (%) 67 (36–76) 62 (43–90) 64 (40–88) 60 (47–88) NA NA
Anticoagulation
Anti-Xa-UFH 0.39 (0.16–0.69) 0.28 (0.1–0.92) 0.33 (0.11–2.25) 0.39 (0.15–2.40) 0.40 (0.10–2.90) 0.36 (0.14–0.57)
Nutrition
– Calories / day 160 (20–650) 770 (10–2410) 1910 (140–3210) 2000 (110–5030) 1960 (60–3810) 1930 (30–2860)
Protein (g/d) 10 (0–30) 50 (0–110) 90 (0–150) 100 (90–260) 100 (0–190) 100 (30–140)
Inflammation/superinfection
– CRP (mg/l) 130 (15–436) 184.5 (16–498) 170 (13–440) 98 (9–433) 73 (4–221) 66 (9–196)
– Antibiotics (n) 18 20 16 10 5 3
– Antifungals (n) 1 1 1 2 0 0
Steroids (n) 3 6 4 4 3 3
CO = cardiac output; CRP = C-reactive protein; ICU = intensive care unit; PEEP = positive end-expiratory pressure ; RASS = Richmond agitation sedation scale; SvO2 = mixed
venous oxygen saturation All values are median (min-max), unless otherwise indicated.
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those of other studies with a higher mortality [4, 5], despite
withholding experimental antiviral or anti-inflammatory
therapies. Here, treatment focused on the best current criti-
cal care practices, including appropriate ventilator settings,
as little fluid as possible, rapid administration of antibi-
otics when bacterial superinfection was suspected, early
enteral nutrition, adequate dialysis, frequent sedation stops
and early mobilisation. Only a small proportion of pa-
tients received steroids, as it was not clear at that time
whether this treatment would be beneficial. However, we
report a higher rate of renal replacement therapy than oth-
ers [16]. We cannot exclude that in some patients the neg-
ative fluid balance achieved contributed to acute renal fail-
ure. Furthermore, sedation and weaning were difficult and
much higher doses of sedatives and opioids were needed in
COVID-19 patients compared with non-COVID-19 ARDS
patients, especially to treat the exaggerated respiratory dri-
ve and to avoid self-inflicted lung injury. This situation
was linked with an increase nurse workload.
One of the most likely explanations for the relatively low
mortality rate we observed might lie in the allocated num-
bers of nurses and physicians per bed, which were both
relatively high compared with European and many North-
and South-American ICUs standards [11, 12]. Similar low
mortality rates have also been reported by others, mostly
when nurse to patient ratios were close to 1:1, when over-
whelming admissions of critically ill patients with
COVID-19 were avoided, and when sufficient well trained
ICU specialists, as well as protective equipment, were
available [17, 18]. However, this single centre observation
is to be validated in future studies, for example by compar-
ing the outcome of COVID-19 patients between ICUs ac-
cording to personal staffing and caseload.
In addition, the recruiting area of the Bern ICU was rela-
tively sparse during the first epidemic wave (maximum in-
cidence around 75/100,000 inhabitants/14 days) compared
with western Switzerland (maximum incidence around
525, 360, 280/100,000 inhabitants/14 days for Geneva,
Vaud and Wallis, respectively) or south Switzerland (max-
imum incidence around 475/100,000 inhabitants/14 days).
We never had to limit ICU admissions and were always
able to adapt the treatment strategy on a daily and individ-
ual-patient basis together with infectious disease special-
ists. At the most, we had 15 patients with COVID-19 si-
multaneously present in our ICU. As the elective surgery
programme had been stopped, we were not forced to open
ICU beds outside the ICU. The high standard of the Swiss
Figure 3: Survival rate in intensive care unit (ICU).
Society of Intensive Care Medicine regarding personnel
assignment and personnel training could thus be fulfilled
over the whole period [19].
These two observations call for a regional and/or national
coordination of ICU admissions of patients with
COVID-19 to minimise the risk of ICU overload and to
secure adequate staffing with specialist nurses and doctors
in ICUs. These high standards are resource consuming and
certainly difficult to fulfil when it comes to open tempo-
rary beds outside of the ICU. Additionally, questions such
as what are the criteria of ICU overload that should trig-
ger the search of mutual aid for patient transfers, what is
the minimum ICU or ICU-equivalent training required for
the staff who will run the expanded beds, what are the min-
imum requirements of these newly open beds in terms of
nurse and physician ratio to insure the sufficient, if not the
best, quality of care to the admitted patients, still remain to
be answered.
The experience from the first wave triggered some im-
provement for the second epidemic wave. First, we ob-
served an increased cooperation between the different
Swiss ICUs, which was even nationwide coordinated. Sec-
ond, our critical care practices remained mostly un-
changed, but we improved and better structured our com-
munication and teaching strategies, with online and
face-to-face workshops, as well as introduction curricula
for new nurses or medical personnel, which include,
among others, training on mechanical ventilation, on prone
positioning procedures, infection control measures, etc.
We further actively promoted partnership/tandem between
critical care nurses and other healthcare professionals. Fi-
nally we offered free meals to all personnel working at the
bedside.
From this experience, we do confirm that medical profes-
sionals who do not regularly work on an ICU require spe-
cial attention. We believe that a “hospital wide strategy”
is needed to make a pool of personnel who are regular-
ly trained in intensive care readily available; these staff
could then rapidly be deployed when needed as the next
epidemics occur. We are currently in the process of imple-
menting such a strategy at our ICU.
In conclusion, we believe that adequate resources (well-
trained ICU staff, available beds, ventilators, other equip-
ment and drugs) and an intensive interdisciplinary ap-
proach helped us to keep mortality low during the first
epidemic wave despite a high degree of organ failure in our
patients.
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